Resolute Science
Developing a novel class of cancer therapeutics for solid tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Resolute Science is pioneering the development of a new class of therapeutics aimed at treating aggressive, difficult-to-treat, and rare solid tumors. The company leverages its proprietary MAC TACs (Macrophage Targeted Conjugates) technology platform to create biomarker-driven, first-in-class synthetic molecules. These molecules are designed to offer superior safety and efficacy compared to existing standard care treatments.
Resolute Science operates in the oncology market, focusing on patients with solid tumors. The business model revolves around the research, development, and commercialization of these novel therapeutics. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
The company's mission is to revolutionize cancer treatment by providing targeted, well-tolerated therapeutics that can be applied across multiple cancer types, ultimately aiming to improve patient outcomes and quality of life.
Keywords: oncology, solid tumors, therapeutics, MAC TACs, biomarker-driven, synthetic molecules, cancer treatment, novel class, patient outcomes, drug delivery.